792 Givastomig, a novel Claudin18.2/4–1BB bispecific antibody, exerts bystander tumor-killing and synergistic anti-tumor activity with therapeutics in 1L/2L treatment for gastric cancer

• Ke Xu,
• Zhengyi Wang,
• Jaeho Jung,
• Xuejun Liu,
• Jie Xia,
• Ao Li,
• Andrew Zhu,
• Jane Meng,
• Chenyu Pan,
• Zhenhu Li

Affiliations

Ke Xu

2I-Mab Biopharma, Shanghai, China

Zhengyi Wang

I-Mab Biopharma, Shanghai, China

Jaeho Jung

ABL Bio Inc, Seongnam, Republic of Korea

Xuejun Liu

1I-Mab Biopharma, San Diego, CA, China

Jie Xia

1Department of Infectious Diseases, Southwest Hospital, Third Military Medical University, Chongqing, China

Ao Li

I-Mab biopharma, Shanghai, China

Andrew Zhu

I-Mab biopharma, Shanghai, China

Jane Meng

3I-Mab Bipharma, Beijing, China

Chenyu Pan

2I-Mab Biopharma, Shanghai, China

Zhenhu Li

2I-Mab Biopharma, Shanghai, China